Author’s response to reviews

Title: New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line

Authors:

Angelika Długosz-Pokorska (angelika.dlugosz@umed.lodz.pl)
Marlena Pięta (marlena.pieta@p.lodz.pl)
Jacek Kędzia (jacek.kedzia@p.lodz.pl)
Tomasz Janecki (tomasz.janecki@p.lodz.pl)
Anna Janecka (anna.janecka@umed.lodz.pl)

Version: 2 Date: 20 Feb 2020

Author’s response to reviews:

Answers to the Editor’s Comments

1. Overlap/iThenticate

We note that the current submission contains some textual overlap with other previously published works, in particular: Długosz-Pokorska, A. et al. (2019) "New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line" https://doi.org/10.1007/s11033-019-05017-w

This overlap mainly exists in the Methods section. While we understand that you may wish to express some of the same ideas contained in these publications, please be aware that we cannot condone the use of text from previously published work. Please be informed that we cannot proceed with handling your manuscript before this issue is resolved, and the sections of text in question have been reformulated.

Answer

The Methods section has been modified.

2. Availability of data and materials

We note that the Availability of data and materials section states that data used by/generated by the study is present both throughout the manuscript and in its supplementary files. However we
note that there are no supplementary files attached to the latest revision of the manuscript. Please either ensure any necessary supplementary files are appropriately uploaded (and that this/these supplementary files are correctly cited in the manuscript), or that alternative sources of this data are mentioned i.e. that further data is available from the corresponding author upon reasonable request.

Answer

The sentence „Availability of data and materials„ has been modified. All data generated or analyzed during the present study are included in this published article.

3. Role of Funders

Please note the role(s) of the funding body (bodies) in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript, which should be declared in the Funding section.

Answer

The funding source had no role in the design of this study and did not play any role during execution, analyses, interpretation of the data or decision to submit results.

4. Acknowledgements

We note that you have not included an acknowledgements section. If you have no acknowledgements please put ‘Not Applicable’ in this section. Please do not include any funding information in your acknowledgements.

Answer

Not applicable.

5. Abbreviations

Please provide a list of all the abbreviations used in the manuscript. This list should be placed just before the Declarations section. All abbreviations should still be defined in the text at first use.

Answer

The abbreviations section has been added as recommended.
6. Formatting

--Please amend the section "Material and Methods" to "Methods"

--Please add the heading "Conclusions" above the concluding paragraph of the Discussion

--Please amend the section "List of Figures" to "Figure Legend"

--Please remove the "Conflict of Interest" section, as the "Competing Interests" section is sufficient

Answer

All sentences have been changed.